Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer

NCT05806931 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Colon Cancer
Rectal Cancer

Interventions

DRUG: TAS-102, oxaliplatin, irinotecan with bevacizumab

Sponsor

Rutgers, The State University of New Jersey